


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant : De Sauvage et al.

Appl. No. : 09/272,835

Filed : March 19, 1999

For : GFRALPHA3 AND ITS USES

Examiner : Hayes, R.

) Group Art Unit 1647

) I hereby certify that this correspondence and all  
) marked attachments are being deposited with the  
) United States Postal Service as first-class mail in  
) an envelope addressed to: Assistant  
) Commissioner for Patents, Washington, D.C.  
) 20231, on

November 8, 2001

(Date)

Ginger R. Dreger, Reg. No. 33,055

SEQUENCE SUBMISSION STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed October 15, 2001. I hereby state that the information recorded in the currently submitted computer readable form of Sequence Listing is identical to the written Sequence Listing submitted herewith as required in 37 CFR § 1.821(f) and (g). I further state that these submissions include no new matter.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: November 8, 2001

By: Ginger R. Dreger

Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660

RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900